GMAB Genmab A/S
Healthcare$26.89+0.07%ClosedMarket Cap: $16.51B
As of 2026-05-26
Valuation
P/E (TTM)
6.33
PEG
—
P/B
2.90
P/S
1.15
EV/EBITDA
5.33
DCF Value
$6.06
FCF Yield
7.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
93.9%
Operating Margin
39.6%
Net Margin
18.2%
ROE
20.5%
ROA
21.1%
ROIC
43.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $899.3M | 92.7% | $225.8M | $53.2M | $— | — |
| Q4 null | $1.05B | 92.3% | $242.3M | $30.9M | $— | — |
| FY null | $3.72B | 91.7% | $1.25B | $963.8M | $— | — |
| Q3 null | $1.02B | 94.3% | $459.0M | $401.0M | $— | — |
| Q2 null | $5.86B | 93.8% | $2.28B | $2.13B | $— | — |
| Q1 null | $715.0M | 94.1% | $188.0M | $195.0M | $— | — |
| Q4 null | $6.44B | 94.8% | $2.16B | $3.85B | $— | — |
| FY null | $21.53B | 95.4% | $6.70B | $7.84B | $— | — |
| Q3 null | $5.54B | 95.1% | $2.10B | $1.27B | $— | — |
| Q2 null | $779.0M | 96.4% | $236.0M | $203.0M | $— | — |
| Q1 null | $603.0M | 95.5% | $116.0M | $192.0M | $— | — |
| Q4 2023 | $4.68B | 97.3% | $1.67B | $640.0M | $0.97 | — |